Characterizing Subsets, Optimizing Expansion & Engineering Against Solid Tumors to Bring Safe, Efficacious, Off-the-Shelf Gamma Delta T Therapies to Patients Faster

July 25-27, 2023 | Boston, MA

Design, Manufacture & Clinically Deliver Safer, More Efficacious, Globally Accessible Treatments for Solid Tumors, Leveraging γδT Mechanisms and Subset-Specific Characteristics

Uncovering In Vivo Mechanisms, Novel Engineering Approaches, Clinical Applications & Optimized Product Design of Allogeneic & Solid Tumor Gamma Delta T Therapies

The gamma delta T wave is cresting as industry leaders such as Adicet Bio, Leucid, Century, Imcheck, IN8bio, Sanofi and Takeda race to demonstrate the clinical benefit and efficacy of gamma delta T therapies, spanning cell-based to antibody and small molecule approaches. Spurred by early evidence of clinical efficacy, the industry returns in 2023 armed with more subset-specific and clinical mechanistic understanding, snowballing investment, and growing expert end-to-end teams. This is the prime time to gather with the gamma delta T therapies industry to contrast subsets, characterize mechanisms of action, and optimize product design to develop globally accessible, solid tumor therapies.

Ensure you don’t miss this comprehensive, forward-facing summit, bringing together 150+ gamma delta T pioneers with 40+ industry-leading speakers including Adrian Hayday, Bruno Silva-Santos and Larry Lamb, collaborating and brainstorming approaches to tackle the most pressing hurdles in this burgeoning field.

Don't miss your chance to to enhance process development, overcome with expert learnings from the 4th Gamma Delta T Therapies Summit.

40+ Expert Speakers Include:

Headshot of Larry Lamb

Lawrence Lamb

Executive Vice President & Chief Scientific Officer


Headshot of Bruno Silva-Santos

Bruno Silva-Santos

Group Leader

Institute of Molecular Medicine - IMM

Headshot of Blake Aftab

Blake Aftab

Chief Scientific Officer

Adicet Bio Inc.

Headshot of Kate Rochlin

Kate Rochlin

Chief Operating Officer


Headshot of Yu Qian

Yu Qian

Associate Director, CMC, Cell Therapies

Takeda Pharmaceutical Co. Ltd.

Headshot of Adrian Hayday

Adrian Hayday

Principal Group Leader

The Francis Crick Institute

Headshot of Dorothee Bourges

Dorothee Bourges

Senior Principal Scientist - Immuno-oncology & Project Leader


Headshot of Rajkumar Ganesan

Rajkumar Ganesan

Executive Director of Immunotherapeutics

Amgen Inc.